Aktuellt
SENASTE
FluoGuide reported Q1 EBIT of DKK -4.2m (vs. SEB at DKK -10.3m) and EPS of DKK -0.32 (vs. SEB at DKK -0.77). The key milestones for 2021 remains (1) results from the first phase clinical study (safety and selection of optimal dose) by Q3/21, (2) efficacy results from the second phase by Q4/21 as well as (3) initiation of a new prevalent indication for FG001. Nothing in the report that changes our view on the case.
LÄS MER
